Ekiz Kimya Sanayi ve Ticaret AS (EKIZ)

Currency in TRY
65.000
+3.500(+5.69%)
Delayed Data·

EKIZ Financial Summary

Key Ratios

P/E Ratio-18.4
Price/Book1.51
Debt / Equity0%
Return on Equity-9.34%
Dividend Yield0.00%
EBITDA-4.81M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of TRY (except for per share items)

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
0.33 / --
Revenue / Forecast
125.47M / --
EPS Revisions
Last 90 days

FAQ

What were Ekiz Kimya's earnings for the latest quarter?

The Ekiz Kimya EPS (TTM) is -2.86. Ekiz Kimya reported sales of 125.47, net income of 3.09, and EPS of 0.33 for the latest quarter.

What was Ekiz Kimya's net income for the latest quarter?

Ekiz Kimya's net income for the latest quarter was 3.09.

How did Ekiz Kimya's performance compare year-over-year in the latest quarter?

The company's revenue moved from 46.07 in the previous quarter to 125.47 in the latest quarter, and net income moved from 13.23 to 3.09 compared to the previous quarter.

What is Ekiz Kimya's net profit margin on a TTM basis?

Ekiz Kimya's trailing twelve months (TTM) net profit margin is 52.32%.

How does Ekiz Kimya's debt to equity ratio compare to industry standards?

Ekiz Kimya's total debt-to-equity ratio is 0.00%.

What is Ekiz Kimya's return on investment on a TTM basis?

Ekiz Kimya's trailing twelve months (TTM) return on investment (ROI) is -9.34%.

Did Ekiz Kimya gain or lose cash last quarter?

In the latest quarter, Ekiz Kimya's net change in cash was 0.02 million.

What were Ekiz Kimya's total assets and liabilities in the latest quarter?

As of the latest quarter, Ekiz Kimya reported total assets of 363.86 million and total liabilities of 37.84 million.

How has Ekiz Kimya's total revenue grown this year?

Ekiz Kimya's total revenue was 46.07 in the previous quarter and 125.47 in the latest quarter.

What is Ekiz Kimya's gross margin on a TTM basis?

Ekiz Kimya's trailing twelve months (TTM) gross margin is 2.72%.

What was Ekiz Kimya's revenue per share for the latest quarter?

Ekiz Kimya's revenue per share for the latest quarter was 45.04.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.